Abstract:Despite a sharp increase in the expenditures for drug research and development (R&D) in the past decade, the declining trend in the number of new drugs approved annually by the US Food and Drug Administration continues. This growing disparity between R&D investment and new drug approvals results in part from the deficiency in promising therapeutic targets and leads to a stagnation exacerbated by the lack of advanced drug discovery tools for harvesting the “high‐hanging fruits” such as inhibitors of protein–protein interactions (PPIs). Small peptide inhibitors of PPIs can be of high affinity and specificity, promising an important class of therapeutic agents that target PPIs involved in a great variety of biological processes. However, susceptibility to proteolytic degradation in vivo still remains a major hurdle that limits their therapeutic potential. This limitation can be overcome by mirror‐image phage display, a technique that allows, through phage‐expressed peptide library screening against the D ‐enantiomer of a target protein, for the identification of proteolysis‐resistant D ‐peptide inhibitors of PPIs. Recent advances in total protein synthesis via native chemical ligation have significantly expanded the scope of molecular targets for mirror‐image phage display. This concise review focuses on the latest development in the combined use of mirror‐image phage display and native chemical ligation for D ‐peptide based anticancer drug discovery.

DNA display for drug discovery

mRNA display: ligand discovery, interaction analysis and beyond

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

The Display Technologies of Molecular Libraries

Chemical Stability of mRNA/cDNA Complexes: Defining the Limits of mRNA display

Advantages of mRNA display selections over other selection techniques for investigation of protein–protein interactions

Biosynthetic phage display: a novel protein engineering tool combining chemical and genetic diversity

D‐Peptide‐Based Drug Discovery Aided by Chemical Protein Synthesis

Selection of DNA‐Encoded Small Molecule Libraries Against Unmodified and Non‐Immobilized Protein Targets

DNA binding and reactivity assays based on in-frame protein expression

Construction of DNA-displaying Nanoparticles by Enzymatic Conjugation of DNA and Elastin-Like Polypeptides Using a Replication Initiation Protein

Peptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors

Nuclease-resistant synthetic drug-DNA adducts: programmable drug-DNA conjugation for targeted anticancer drug delivery

DNA Nanotechnology-Enabled Drug Delivery Systems.

A promising nucleic acid therapy drug: DNAzymes and its delivery system

Directed Evolution Using Stabilized Bacterial Peptide Display

A Targeted DNAzyme-Nanocomposite Probe Equipped with Built-in Zn2+ Arsenal for Combined Treatment of Gene Regulation and Drug Delivery

Recent Advances in Non‐Standard Macrocyclic Peptide Ligand Discovery using mRNA Display

Front Cover: Drug‐grafted DNA As a Novel Chemogene for Targeted Combinatorial Cancer Therapy (EXP2 2/2022)

Phage display technology and its impact in the discovery of novel protein-based drugs

Screening and Optimization of Phage Display Cyclic Peptides Against the WDR5 WBM Site